Alvotech stock (LU2557688560): Q1 2026 revenue dip and EBITDA rise on mix shift

Alvotech reports weaker Q1 2026 revenue but higher EBITDA as manufacturing upgrades and a product mix shift reshape its financial profile.

Alvotech stock has come under renewed scrutiny after the company disclosed its first?quarter 2026 results, which showed a roughly 20% year?on?year revenue decline alongside a rise in EBITDA driven by a favorable product mix and ongoing manufacturing enhancements. Trading near 52?week lows with a market capitalization of about $1.12 billion, down from a 52?week high of $11.85 billion, Alvotech faces investor skepticism about its near?term execution even as management reaffirms full?year guidance and outlines new biosimilar and manufacturing initiatives. The stock traded at around 5.09 USD on May 10, 2026, on Nasdaq, according to StockAnalysis as of 05/10/2026.

During the Q1 2026 earnings call, Alvotech executives highlighted that first?quarter priorities centered on advancing U.S. regulatory work, maintaining inspection readiness, and expanding commercial activity globally while the company works through manufacturing enhancements at its Reykjavik facility. The company also noted that production interruptions during facility upgrades contributed to weaker top?line performance in the quarter, even as higher?margin products and improved operational efficiency helped lift EBITDA. Management reiterated its full?year 2026 guidance, signaling confidence that the current mix shift and capacity investments will support stronger performance in the second half of the year, according to Investing.com as of 05/07/2026.

As of: 10.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Alvotech
• Sector/industry: Biopharmaceuticals / biosimilars
• Headquarters/country: Iceland
• Core markets: United States, Europe and other global markets
• Key revenue drivers: Biosimilar medicines and related partnerships
• Home exchange/listing venue: Nasdaq Global Market (ticker: ALVO)
• Trading currency: USD

Alvotech: core business model

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide, aiming to expand access to affordable biologic therapies. The company focuses on high?value biologics used in areas such as autoimmune diseases, oncology and other chronic conditions, where branded originator drugs often carry very high price tags. By producing biosimilars that are highly similar to these reference products, Alvotech seeks to lower treatment costs for payers and patients while maintaining comparable safety and efficacy profiles, according to StockAnalysis as of 05/10/2026.

Alvotech’s business model combines in?house research and development with contract manufacturing and commercial partnerships, allowing it to share development and commercialization risks with larger pharmaceutical partners. The company operates a manufacturing facility in Reykjavik, Iceland, which serves as a central hub for its global supply chain and regulatory filings. This vertically integrated approach enables Alvotech to control key stages of the biosimilar lifecycle, from cell?line development and process optimization to large?scale production and quality control, according to Alvotech Newsroom as of 05/10/2026.

Main revenue and product drivers for Alvotech

Alvotech’s main revenue streams stem from sales of approved biosimilar products and milestone and royalty payments tied to its partnership agreements. The company’s portfolio includes biosimilars targeting widely used biologics such as tumor necrosis factor (TNF) inhibitors and other monoclonal antibodies, which are prescribed for conditions like rheumatoid arthritis, inflammatory bowel disease and psoriasis. These products are commercialized in the United States, Europe and other regions through collaborations with established pharmaceutical companies that handle distribution, marketing and payer negotiations, according to Alvotech Newsroom as of 05/10/2026.

In Q1 2026, Alvotech reported a revenue decline of about 20% year?on?year, largely due to production interruptions during facility upgrades and a temporary shift in product mix. However, the company also noted that higher?margin products and improved manufacturing efficiency contributed to a rise in EBITDA, indicating that the underlying profitability of its operations is improving even as top?line growth remains under pressure. Management emphasized that the current mix shift is intentional, as it aligns production capacity with higher?value biosimilars and prepares the Reykjavik plant for future volume increases, according to Investing.com as of 05/07/2026.

Why Alvotech matters for US investors

For US investors, Alvotech represents a leveraged play on the growing biosimilar market, which is expected to expand as patent expirations for major biologics accelerate and payers push for lower?cost alternatives. The company’s Nasdaq listing and focus on U.S. regulatory approvals make it directly accessible to American retail and institutional investors, while its partnerships with large pharma players provide a degree of commercial de?risking. At the same time, Alvotech’s relatively small market capitalization and dependence on a limited number of products and facilities expose it to higher volatility and execution risk, according to Simply Wall St as of 05/07/2026.

Recent developments, including the Q1 2026 revenue dip and the ongoing manufacturing enhancements, highlight both the opportunities and risks inherent in Alvotech’s model. On one hand, successful execution of its facility upgrades and pipeline expansion could position the company to capture a larger share of the U.S. biosimilar market and improve margins over time. On the other hand, any further delays in regulatory approvals, production setbacks or competitive pressures from other biosimilar manufacturers could weigh on the stock and delay the realization of these growth prospects, according to Investing.com as of 05/07/2026.

Conclusion

Alvotech’s Q1 2026 results underscore a transitional phase in which short?term revenue pressure coexists with improving profitability and strategic capacity investments. The roughly 20% year?on?year revenue decline reflects production interruptions and a deliberate product mix shift, while the rise in EBITDA points to stronger underlying margins and operational discipline. Trading near 52?week lows with a market capitalization of about $1.12 billion, the stock remains sensitive to execution risks around manufacturing upgrades and regulatory timelines, according to Investing.com as of 05/07/2026.

For US investors, Alvotech offers exposure to the expanding biosimilar market through a Nasdaq?listed vehicle with a focused pipeline and established partnerships. However, the company’s relatively small size, concentrated product base and dependence on a single manufacturing site mean that any setbacks in production, approvals or competition could lead to significant volatility. As such, Alvotech may appeal to investors comfortable with higher risk and longer time horizons, while more conservative investors may prefer to monitor the company’s progress through upcoming quarters and regulatory milestones, according to Simply Wall St as of 05/07/2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.